Stage IV Gastric Cancer With Metastasis Clinical Trial
Official title:
The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer
This study is to determine the response rate and safety profile of irinotecan plus epirubicin as the second-line chemotherapy for advanced gastric cancer and fully evaluate the feasibility and effectiveness of the regime.
The main purposes: to determine the progression-free survival (PFS) and overall survival
(OS) of gastric cancer patients given irinotecan + epirubicin as second-line treatment, who
are at Stage IV with disease progressed or recurred after first-line chemotherapy failed, ,
The Secondary purposes: to determine disease control rate (Disease Control Rate, DCR), the
objective response rate (Object Response rate, ORR) and the Quality of life (Quality Of
Life, QOL)
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03604614 -
Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer With Peritoneal Metastatis
|
Phase 2 | |
| Not yet recruiting |
NCT05441254 -
Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study
|
Phase 2 | |
| Active, not recruiting |
NCT03237507 -
Nonintervention Study on Peritoneal Metastasis of Stage IV Gastric Cancer
|
N/A | |
| Completed |
NCT01525771 -
Safety Study of Combined Systemic and Intraperitoneal Chemotherapy to Treat Stomach Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01503983 -
Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive
|
Phase 2 |